Rowlandmiller & Partners’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.76M | Sell |
37,007
-25
| -0.1% | -$2.93K | 0.87% | 28 |
|
|
2026
Q1 | $4.45M | Sell |
37,032
-2,317
| -6% | -$267K | 0.9% | 29 |
|
|
2025
Q4 | $4.14M | Sell |
39,349
-984
| -2% | -$92.4K | 0.8% | 30 |
|
|
2025
Q3 | $3.39M | Sell |
40,333
-565
| -1% | -$46.5K | 0.66% | 41 |
|
|
2025
Q2 | $3.24M | Buy |
40,898
+200
| +0.5% | +$15.9K | 0.67% | 41 |
|
|
2025
Q1 | $3.65M | Sell |
40,698
-1,850
| -4% | -$173K | 0.77% | 36 |
|
|
2024
Q4 | $4.23M | Sell |
42,548
-1,000
| -2% | -$103K | 0.88% | 34 |
|
|
2024
Q3 | $4.95M | Buy |
43,548
+70
| +0.2% | +$8.32K | 1% | 31 |
|
|
2024
Q2 | $5.38M | Sell |
43,478
-1,935
| -4% | -$249K | 1.17% | 25 |
|
|
2024
Q1 | $5.99M | Buy |
45,413
+90
| +0.2% | +$11.1K | 1.26% | 25 |
|
|
2023
Q4 | $4.94M | Sell |
45,323
-545
| -1% | -$56.6K | 1.13% | 28 |
|
|
2023
Q3 | $4.72M | Sell |
45,868
-134
| -0.3% | -$14.4K | 1.17% | 29 |
|
|
2023
Q2 | $5.31M | Sell |
46,002
-151
| -0.3% | -$17.1K | 1.25% | 27 |
|
|
2023
Q1 | $4.91M | Sell |
46,153
-245
| -0.5% | -$26.5K | 1.19% | 28 |
|
|
2022
Q4 | $5.16M | Hold |
46,398
| – | – | 1.28% | 24 |
|
|
2022
Q3 | $4M | Sell |
46,398
-45
| -0.1% | -$4.02K | 1.08% | 31 |
|
|
2022
Q2 | $4.23M | Hold |
46,443
| – | – | 1.08% | 31 |
|
|
2022
Q1 | $3.81M | Sell |
46,443
-34
| -0.1% | -$2.68K | 0.88% | 37 |
|
|
2021
Q4 | $3.56M | Buy |
46,477
+30
| +0.1% | +$2.39K | 0.8% | 39 |
|
|
2021
Q3 | $3.59M | Sell |
46,447
-670
| -1% | -$51K | 1.22% | 28 |
|
|
2021
Q2 | $3.66M | Sell |
47,117
-2,204
| -4% | -$164K | 0.9% | 34 |
|
|
2021
Q1 | $3.63M | Buy |
49,321
+1,056
| +2% | +$77.9K | 0.95% | 36 |
|
|
2020
Q4 | $3.77M | Sell |
48,265
-411
| -0.8% | -$31.4K | 1.07% | 30 |
|
|
2020
Q3 | $3.57M | Hold |
48,676
| – | – | 1.43% | 21 |
|
|
2020
Q2 | $3.59M | Hold |
48,676
| – | – | 1.22% | 28 |
|
|
2020
Q1 | $3.57M | Sell |
48,676
-509
| -1% | -$40K | 1.43% | 21 |
|
|
2019
Q4 | $4.27M | Buy |
49,185
+24
| +0% | +$1.97K | 1.33% | 26 |
|
|
2019
Q3 | $3.99M | Sell |
49,161
-317
| -0.6% | -$25.4K | 1.35% | 26 |
|
|
2019
Q2 | $3.93M | Sell |
49,478
-534
| -1% | -$40.9K | 1.36% | 25 |
|
|
2019
Q1 | $3.97M | Sell |
50,012
-482
| -1% | -$36K | 1.42% | 24 |
|
|
2018
Q4 | $3.68M | Sell |
50,494
-56
| -0.1% | -$3.95K | 1.49% | 21 |
|
|
2018
Q3 | $3.42M | Sell |
50,550
-105
| -0.2% | -$6.69K | 1.24% | 30 |
|
|
2018
Q2 | $2.93M | Sell |
50,655
-314
| -0.6% | -$17.7K | 1.14% | 30 |
|
|
2018
Q1 | $2.66M | Buy |
50,969
+2,923
| +6% | +$158K | 1.05% | 33 |
|
|
2017
Q4 | $2.59M | Sell |
48,046
-2,122
| -4% | -$118K | 1.01% | 32 |
|
|
2017
Q3 | $3.05M | Sell |
50,168
-1,742
| -3% | -$106K | 1.27% | 28 |
|
|
2017
Q2 | $3.18M | Sell |
51,910
-3,930
| -7% | -$239K | 1.35% | 29 |
|
|
2017
Q1 | $3.38M | Sell |
55,840
-350
| -0.6% | -$21.2K | 1.49% | 25 |
|
|
2016
Q4 | $3.16M | Sell |
56,190
-497
| -0.9% | -$29.1K | 1.43% | 26 |
|
|
2016
Q3 | $3.38M | Sell |
56,687
-210
| -0.4% | -$12.3K | 1.56% | 24 |
|
|
2016
Q2 | $3.12M | Buy |
56,897
+1,441
| +3% | +$76.7K | 1.44% | 23 |
|
|
2016
Q1 | $2.8M | Buy |
55,456
+1,782
| +3% | +$87.3K | 1.32% | 28 |
|
|
2015
Q4 | $2.66M | Sell |
53,674
-603
| -1% | -$30.4K | 1.35% | 26 |
|
|
2015
Q3 | $2.53M | Buy |
54,277
+142
| +0.3% | +$7.54K | 1.34% | 24 |
|
|
2015
Q2 | $2.94M | Sell |
54,135
-210
| -0.4% | -$11.8K | 1.46% | 23 |
|
|
2015
Q1 | $2.93M | Buy |
54,345
+126
| +0.2% | +$7.13K | 1.46% | 24 |
|
|
2014
Q4 | $2.94M | Buy |
+54,219
| New | +$3.02M | 1.42% | 24 |
|
Other funds holding MRK
ECSS
Rowlandmiller & Partners's MRK Position: Q2 2026 in Review
Rowlandmiller & Partners reduced its Merck (MRK) stake by 0.07% in Q2 2026, selling an estimated $2.93K and leaving 37,007 shares worth $4.76M. The position accounts for 0.87% of the portfolio, ranked #28.
Rowlandmiller & Partners first reported a position in MRK in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.99M in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Rowlandmiller & Partners held 37,007 shares of Merck worth $4.76M as of Q2 2026.
- Rowlandmiller & Partners sold 25 Merck shares in Q2 2026, an estimated $2.93K.
- Merck made up 0.87% of Rowlandmiller & Partners's portfolio in Q2 2026, its #28 holding.
- Rowlandmiller & Partners first reported a position in Merck in Q4 2014 and has held it in 47 quarters since.
- Rowlandmiller & Partners's Merck position peaked at $5.99M in Q1 2024.
- 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.